Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Dapagliflozin in Patients with Membranous Nephropathy.
Chertow GM, Heerspink HL, Mark PB, Dwyer JP, Nowicki M, Wheeler DC, Correa-Rotter R, Rossing P, Toto RD, Langkilde AM, Jongs N. Chertow GM, et al. Among authors: mark pb. Glomerular Dis. 2024 Jun 21;4(1):137-145. doi: 10.1159/000539770. eCollection 2024 Jan-Dec. Glomerular Dis. 2024. PMID: 39144475 Free PMC article.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC; DAPA-CKD Investigators. Heerspink HJL, et al. Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282. doi: 10.1093/ndt/gfz290. Nephrol Dial Transplant. 2020. PMID: 32030417 Free PMC article. Clinical Trial.
Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.
Macdougall IC, Bhandari S, White C, Anker SD, Farrington K, Kalra PA, Mark PB, McMurray JJV, Reid C, Robertson M, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees. Macdougall IC, et al. Among authors: mark pb. J Am Soc Nephrol. 2020 May;31(5):1118-1127. doi: 10.1681/ASN.2019090972. Epub 2020 Apr 6. J Am Soc Nephrol. 2020. PMID: 32253271 Free PMC article. Clinical Trial.
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop.
O'Lone E, Viecelli AK, Craig JC, Tong A, Sautenet B, Herrington WG, Herzog CA, Jafar TH, Jardine M, Krane V, Levin A, Malyszko J, Rocco MV, Strippoli G, Tonelli M, Wang AYM, Wanner C, Zannad F, Winkelmayer WC, Wheeler DC; SONG-HD CVD Consensus Workshop Investigators. O'Lone E, et al. Am J Kidney Dis. 2020 Jul;76(1):109-120. doi: 10.1053/j.ajkd.2020.01.022. Epub 2020 May 12. Am J Kidney Dis. 2020. PMID: 32414662
Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Free article. Clinical Trial.
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Eur Heart J. 2021 Mar 31;42(13):1216-1227. doi: 10.1093/eurheartj/ehab094. Eur Heart J. 2021. PMID: 33792669 Free PMC article. Clinical Trial.
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Kidney Int. 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560136 Free article. Clinical Trial.
An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.
Thomson PC, Mark PB, Robertson M, White C, Anker SD, Bhandari S, Farrington K, Jardine AG, Kalra PA, McMurray J, Reddan D, Wheeler DC, Winearls CG, Ford I, Macdougall IC; PIVOTAL Investigators and Committees. Thomson PC, et al. Among authors: mark pb. Kidney Int Rep. 2022 May 18;7(8):1793-1801. doi: 10.1016/j.ekir.2022.05.008. eCollection 2022 Aug. Kidney Int Rep. 2022. PMID: 35967105 Free PMC article.
276 results